vimarsana.com
Home
Live Updates
Risankizumab Provides Durable Quality of Life Improvements o
Risankizumab Provides Durable Quality of Life Improvements o
Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis
An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.
Related Keywords
Italy ,
Milan ,
Lombardia ,
Lars Erik Kristensen ,
Eli Lilly ,
Amgen ,
Parker Institute ,
European Congress ,
Pfizer ,
Novartis ,
Bristol Myers Squibb ,
European Congress On Rheumatology ,
Ann Rheum ,